

Novel Strategy for the Formulation of Poorly Water-Soluble Drugs: Nystatin Microencapsulation [†]

Noelia Pérez-González ^{1,*}, María J. Martín-Villena ¹, Ana C. Calpena-Campmany ², José A. Morales-Molina ^{3,4} and Beatriz Clares-Naveros ^{1,4}

¹ Department of Pharmacy and Pharmaceutical Technology, Faculty of Pharmacy, University of Granada, 18071 Granada, Spain; mjoemv85@gmail.com (M.J.M.-V.); beatrizclares@ugr.es (B.C.-N.)

² Department of Pharmacy and Pharmaceutical Technology and Physical Chemistry, Faculty of Pharmacy and Food Sciences, University of Barcelona, 08028 Barcelona, Spain; anacalpena@ub.edu

³ Pharmacy Department, Torrecárdenas Hospital, 04009 Almería, Spain; jomomo01@gmail.com

⁴ Biomedical Research Institute ibs.Granada, 18014 Granada, Spain

* Correspondence: noeliaperezgonzalez93@hotmail.com

[†] Presented at the 1st International Electronic Conference on Pharmaceutics, 1–15 December 2020;

Available online: <https://iecp2020.sciforum.net/>.

Abstract: Background: In recent years, a growing concern about resistance to anti-infective agents has emerged. One of the most common microbial agents is *Candida albicans*. Under certain conditions, *C. albicans* can cause infections of skin and mucosal tissues. Nystatin (Nys) is a broad-spectrum antifungal, which is indicated for the treatment of mucosal infections caused by *Candida* spp such as patients under radiological treatment. Nys is a photosensitive drug and very poorly soluble in aqueous media. Therefore, microencapsulation can be the solution for its limiting factors. **Purpose:** The aim of this work was to design, develop and characterize two types of microparticles as appropriate nystatin delivery systems for topical use: alginate microparticles (AM) and chitosan coated alginate microparticles (CCM). **Methods:** The formulation of the microparticles was based on the emulsification/internal gelation methodology with modification. First, a water in oil W/O emulsion was created. Sodium alginate aqueous solution, CaCO₃ and Nys were the ingredients of the internal phase, and vegetable oil the external phase. The resulting microparticles were characterized in terms of particle size, percentage yield (PY), loading capacity (LD), encapsulation efficiency (EE) and mucoadhesion ability. **Results and Discussion:** Microparticles ranged from 51.21 µm for AM to 57.20 µm for CCM. The PY values were 83.26% and for 79.67% AM and CCM, respectively. The LD values for the inside/surface were 6.78%/0.40% for AM and 4.87%/0.91% for CCM. The values of EE for inside and surface were 81.12%/12.07% for AM and 85.08%/9.19% for CCM. CCM was the system that exhibited the best mucoadhesive properties. **Conclusions:** The ability of these systems to adhere to mucous membranes has great appeal for the treatment of localized infections. Thus, these microparticulate systems could be proposed as a suitable vehicle for this kind of mucosal infections, being an alternative therapy.

Supplementary Materials: The following are available online at <https://www.mdpi.com/article/10.3390/IECP2020-08898/s1>.

Institutional Review Board Statement: Not applicable.

Informed Consent Statement: Not applicable.

Data Availability Statement: Not applicable.

Citation: Pérez-González, N.; Martín-Villena, M.J.; Calpena-Campmany, A.C.; Morales-Molina, J.A.; Clares-Naveros, B. Novel Strategy for the Formulation of Poorly Water-Soluble Drugs: Nystatin Microencapsulation. *Proceedings* **2021**, *78*, 41. <https://doi.org/10.3390/IECP2020-08898>

Published: 4 December 2020

Publisher's Note: MDPI stays neutral with regard to jurisdictional claims in published maps and institutional affiliations.



Copyright: © 2020 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (<http://creativecommons.org/licenses/by/4.0/>).

References

1. Fernández-Campos, F.; Clares-Naveros, B.; López-Serrano, O.; Alonso-Merino, C.; Calpena-Campmany, A.C. Evaluation of Novel Nystatin Nanoemulsion for Skin Candidosis Infections. *Mycoses* **2013**, *56*, 70–81.
2. Offner, F.; Krcmery, V.; Boogaerts, M.; Doyen, C.; Engelhard, D.; Ribaud, P.; Cordonnier, C.; De Pauw, B.; Durrant, S.; Marie, J.-P.; et al. Liposomal Nystatin in Patients with Invasive Aspergillosis Refractory to or Intolerant of Amphotericin B. *Antimicrob. Agents Chemother.* **2004**, *48*, 4808–4812.
3. Agarwal, S.; Thakur, K.; Kanga, A.; Singh, G.; Gupta, P. Catheter-related candidemia caused by *Candida lipolytica* in a child with tubercular meningitis. *Indian J. Pathol. Microbiol.* **2008**, *51*, 298–300.
4. Silva, C.M.; Ribeiro, A.J.; Ferreira, D.; Veiga, F. Insulin encapsulation in reinforced alginate microspheres prepared by internal gelation. *Eur. J. Pharm. Sci.* **2006**, *29*, 148–159.